Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 5 of 7 for:    aducanumab | Alzheimer Disease

Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Participants With Alzheimer's Disease (PROPEL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02434718
Recruitment Status : Completed
First Posted : May 5, 2015
Last Update Posted : April 10, 2017
Sponsor:
Information provided by (Responsible Party):
Biogen

Brief Summary:
The primary objective of the study is to evaluate the safety and tolerability of single and multiple intravenous (IV) infusions of Aducanumab in Japanese participants with mild to moderate Alzheimer's Disease (AD). The secondary objectives of this study are as follows: To evaluate the serum pharmacokinetics (PK) of Aducanumab after single and multiple intravenous (IV) infusions of Aducanumab; To evaluate the effect of single and multiple IV infusions of Aducanumab on immunogenicity.

Condition or disease Intervention/treatment Phase
Alzheimer's Disease Drug: Aducanumab Drug: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 21 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Aducanumab (BIIB037) in Japanese Subjects With Mild to Moderate Alzheimer's Disease
Actual Study Start Date : June 30, 2015
Actual Primary Completion Date : December 9, 2016
Actual Study Completion Date : December 9, 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Cohort 1
IV infusion in cohorts assigned to low dose 1; 1 participant per cohort will receive placebo
Drug: Aducanumab
As described in the treatment arm

Drug: Placebo
IV administration of 0.9% sodium chloride

Experimental: Cohort 2
IV infusion in cohorts assigned to low dose 2; 1 participant per cohort will receive placebo
Drug: Aducanumab
As described in the treatment arm

Drug: Placebo
IV administration of 0.9% sodium chloride

Experimental: Cohort 3
IV infusion in cohorts assigned to high dose; 1 participant per cohort will receive placebo
Drug: Aducanumab
As described in the treatment arm

Drug: Placebo
IV administration of 0.9% sodium chloride

Experimental: Cohort 4
IV infusion in cohorts assigned to mid dose; 1 participant per cohort will receive placebo
Drug: Aducanumab
As described in the treatment arm

Drug: Placebo
IV administration of 0.9% sodium chloride




Primary Outcome Measures :
  1. Incidence and nature of adverse events (AE) / serious adverse events(SAE) [ Time Frame: Up to week 42 ]
  2. Clinically significant changes in vital signs and 12-lead electrocardiogram (ECG) data; abnormalities in neurological and physical examinations [ Time Frame: Up to week 42 ]
  3. Brain magnetic resonance imaging (MRI) findings to assess amyloid-related imaging abnormalities (ARIA), including incidence of ARIA-E (edema) or ARIA-H (hemosiderosis) [ Time Frame: Up to week 42 ]

Secondary Outcome Measures :
  1. Area under the concentration-time curve (AUC) from time zero extrapolated to infinity (AUC0-∞) [ Time Frame: Up to 8 weeks post dosing ]
  2. AUC from time zero to time of the last measurable concentration (AUC0-last) [ Time Frame: Up to 8 weeks post dosing ]
  3. Maximum observed concentration (Cmax) [ Time Frame: Up to 8 weeks post dosing ]
  4. Time to Cmax (Tmax) [ Time Frame: Up to 8 weeks post dosing ]
  5. Elimination half-life (t1/2) [ Time Frame: Up to 8 weeks post dosing ]
  6. Volume of distribution at steady state (Vss) [ Time Frame: Up to 8 weeks post dosing ]
  7. Clearance (CL) after a single IV infusion of aducanumab [ Time Frame: Up to 8 weeks post dosing ]
  8. Incidence of anti-aducanumab antibodies in serum [ Time Frame: Up to week 42 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   55 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Must be ambulatory
  • Must have a clinical diagnosis of mild to moderate AD
  • Must be in good health as determined by the Investigator, based on medical history and Screening assessments
  • Must have a caregiver who, understands the study and assents to accompany the subject to all study site visits, provide information to the Investigator/study site staff, specifically about cognitive abilities and AEs/SAEs and return for per-protocol follow-up visits and procedures
  • Must consent to blood sample collection for deoxyribonucleic acid (DNA; genotyping) and ribonucleic acid (RNA; for potential future analysis).

Key Exclusion Criteria:

  • Any medical or neurological condition (other than AD) that in the opinion of the Investigator could be a contributing cause of the subject's dementia
  • Transient ischemic attack or stroke or any unexplained loss of consciousness within 1 year prior to Screening
  • Poorly controlled diabetes mellitus, as defined by having dosage adjustment of diabetic medication within the 3 months prior to Day 1
  • History of unstable angina, myocardial infarction, chronic heart failure
  • Chronic, uncontrolled hypertension
  • History of seizure within 3 years prior to Screening
  • History within the past 6 months or evidence of clinically significant psychiatric illness
  • History of severe allergic or anaphylactic reactions, or history of hypersensitivity to any of the inactive ingredients in the drug product

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02434718


Locations
Layout table for location information
Japan
Research Site
Toon, Ehime, Japan
Research Site
Kobe, Hyogo, Japan
Research Site
Kamakura, Kanagawa, Japan
Research Site
Kanzaki, Saga, Japan
Research Site
Kodaira, Tokoyo, Japan
Research Site
Shinjuku, Tokoyo, Japan
Research Site
Kyoto, Japan
Sponsors and Collaborators
Biogen
Investigators
Layout table for investigator information
Study Director: Medical Director Biogen

Layout table for additonal information
Responsible Party: Biogen
ClinicalTrials.gov Identifier: NCT02434718     History of Changes
Other Study ID Numbers: 221AD104
First Posted: May 5, 2015    Key Record Dates
Last Update Posted: April 10, 2017
Last Verified: April 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders